Clinical ink company overview
About
Expert Vetted Data
Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former Clinical ink executives.
Ownership & Key Financials
Revenue
Investors
Revenue / FTE
Ownership
FTEs
Key Business Breakdowns
Products & Services
Wearables Integration
Tools to capture data from patient wearables and sensors (e.g. activity trackers, medical devices) and incorporate these digital endpoints into the eS••••• ••••••••.
Neurocognitive Assessment & Digital Biomarkers
••••••••••• •••••••• ••• ••••••••• ••••••• ••• ••••••• •••••• •••• •••••••••• •• ••• ••••••, ••••••••• •• ••• •••• ••••••• ••••••••• •••••••••••.
Telehealth Visit Solution
•••••••••• •••••••••••••• •••••• •• ••••••• •••••• ••••• •••••• ••• •••••••••••, •••••••••• ••••••••••••• ••••• •••••••••••••.
Electronic Consent Management (eConsent)
•••••• •••••• •••••••• ••• ••••••••• ••• •••••••• ••••••• •••••••• •••••••, ••••••••• ••••• ••••••• ••••• ••• •••••••• •• ••• •••• •• ••••••••••.
Electronic Clinical Outcome Assessment (eCOA) Tools
Digital solutions including ePRO for patients and clinician-reported outcomes to collect trial outcomes via mobile devices and web, enabling real-time •••••••-•••••••• •••• •••••••.
Electronic Data Capture Platform (eSource)
•••••-••••• ••••••• •••••• ••• ••••••••• •••••••• ••••• •••• •• ••• ••••• •• ••••, ••••••••••• ••••• ••••• ••• •••••••••••• •••• ••••••••••••.
EDCXtra™
•••-••••• ••• •••••••• ••••••• •••• •••••••• •••'• •••••• •••• ••••••• ••• •••• ••••••••, •••••••• •• •••••• ••••.
Pricing & Go-to-market
Typical Contract Length
•••••••• ••••••• ••• ••••• •• ••••• ••••••••, ••••••••• •-• •••••.
Pricing model
••••••••••••-••••• ••••••• ••••• •• ••• •••••••••• ••• ••••• •• ••••••••••••• •• ••• •••••.
Growth Review
Customer Overview
•. •• •••••••••, ••••••••• •••••••••••••• ••••••••• •••••• •••••••• ••••••••••• •••••, •••• • ••••• •• •••••••••.
Customer Concentration
••• ••• •• ••••••••• ••••••• ••• •. ••% •• ••• •••••••.
Key Purchasing Criteria
••••••••••••• ••• •••• ••••••• •••••••.
| Company Name | Revenue | FTE | Proprietary Insights | HQ | Ownership Type |
|---|---|---|---|---|---|
 Clinical ink | - | ••• '•• | - | USA | P•••••••• |
 CRIO | - | - | - | - | - |
 Medable | - | - | - | - | - |
 Oracle | - | - | - | - | - |
 Science 37 | - | - | - | - | - |
 Medidata Solutions | - | - | - | - | A••••••• |
| C Castor | - | - | - | - | - |
 Veeva | - | - | - | - | - |
 Signant Health | - | - | - | - | - |
Experts highlight Clinical ink's strong customer relationships and retention, while noting market evolution and timing considerations as a potential constraint.
What does Origin provide on Clinical ink?
Origin provides a structured company snapshot of Clinical ink, combining expert-led insights with analysis across business model, customers, competitors, and market dynamics. The profile is designed to support research, competitive analysis, and commercial due diligence workflows.
How is Origin's analysis of Clinical ink different from traditional company databases?
Traditional company databases often focus on surface-level metadata such as ownership, funding, and company descriptions. Origin complements these sources with qualitative insights informed by expert interviews, helping teams understand how Clinical ink operates, competes, and creates value in practice.
Is Origin suitable for researching private companies like Clinical ink?
Yes. Origin is built to support research on private companies, where public information can be limited or inconsistent. It focuses on insight depth and operational context, which can be useful when evaluating companies like Clinical ink for investment, partnership, or competitive analysis.
Where does Origin's information on Clinical ink come from?
Origin insights are derived from expert interviews conducted by Dialectica, combined with structured analysis and secondary validation where appropriate. This approach prioritises first-hand operational perspectives alongside supporting evidence, rather than relying solely on aggregated public data.
Can Origin support commercial due diligence on Clinical ink?
Origin can support early-stage commercial due diligence by helping teams quickly understand positioning, value drivers, customer dynamics, and potential risks related to Clinical ink. It is typically used to shape hypotheses and focus areas before deeper primary research.
How does Origin compare to Crunchbase or PitchBook for analysing Clinical ink?
Crunchbase and PitchBook primarily focus on company metadata, ownership, funding history, and transactions. Origin complements those sources by adding qualitative, insight-led analysis focused on business fundamentals, go-to-market execution, customer reality, and competitive positioning for companies like Clinical ink.
How can Origin support portfolio monitoring or add-on analysis for companies like Clinical ink?
For PE-backed contexts, Origin can support monitoring by surfacing changes in competitive intensity, customer demand signals, and go-to-market effectiveness. It can also inform add-on analysis by clarifying adjacency opportunities and how a target like Clinical ink may fit within a broader platform strategy.
What does Origin typically reveal about pricing and go-to-market strategy for enterprise software companies like Clinical ink?
For enterprise software, Origin often focuses on pricing logic, contract structure, buyer personas, procurement friction, and channel strategy. For companies like Clinical ink, this can help teams assess how revenue is created, what drives expansion, and where sales cycles or retention may impact outcomes.
Relevant Companies
Axxess
Cloud-based home healthcare software platform for home health, home care, hospice, and palliative care providers to manage care quality, compliance, patient engagement, and financial operations.
HQ
Ownership
DexCare
Platform-as-a-Service care-access orchestration for healthcare systems to guide patients to the right care and optimize resource utilization.